Profusa (NASDAQ:PFSA) Shares Scheduled to Reverse Split on Tuesday, July 7th

Shares of Profusa, Inc. (NASDAQ:PFSA) are going to reverse split on Tuesday, July 7th. The 1-25 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Monday, July 6th.

Profusa Stock Performance

Profusa stock remained flat at $0.09 during trading hours on Friday. The company’s stock had a trading volume of 6,920,470 shares, compared to its average volume of 7,929,186. Profusa has a 12 month low of $0.08 and a 12 month high of $180.00. The firm has a fifty day simple moving average of $0.33 and a two-hundred day simple moving average of $2.53.

Profusa (NASDAQ:PFSA) last announced its quarterly earnings results on Friday, May 15th. The company reported ($2.05) earnings per share for the quarter.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the stock. Wall Street Zen upgraded shares of Profusa from a “strong sell” rating to a “sell” rating in a report on Saturday, April 18th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Profusa in a report on Wednesday, June 24th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of “Sell”.

Profusa Company Profile

Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.

The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.